Comparison 12. Target of rapamycin inhibitors (TOR‐I) versus calcineurin inhibitors (CNI): subgroup analyses.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 All acute rejection (publication type)	19	3016	Risk Ratio (M‐H, Random, 95% CI)	1.59 [1.31, 1.92]
1.1 Abstract	3	228	Risk Ratio (M‐H, Random, 95% CI)	2.03 [1.13, 3.65]
1.2 Journal	16	2788	Risk Ratio (M‐H, Random, 95% CI)	1.56 [1.26, 1.92]
2 All acute rejection (risk of bias for sequence generation and allocation concealment)	19	3016	Risk Ratio (M‐H, Random, 95% CI)	1.59 [1.31, 1.92]
2.1 Low risk of bias	7	1841	Risk Ratio (M‐H, Random, 95% CI)	1.45 [0.98, 2.15]
2.2 High or unclear risk of bias	12	1175	Risk Ratio (M‐H, Random, 95% CI)	1.70 [1.35, 2.14]
3 All acute rejection (CNI comparator)	19		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1 Tacrolimus	7	1384	Risk Ratio (M‐H, Random, 95% CI)	2.19 [1.71, 2.81]
3.2 Cyclosporin	13	2233	Risk Ratio (M‐H, Random, 95% CI)	1.48 [1.20, 1.83]
4 All acute rejection (antibody induction)	17	2795	Risk Ratio (M‐H, Random, 95% CI)	1.60 [1.29, 1.99]
4.1 No induction	4	307	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.91, 1.68]
4.2 Antibody induction	13	2488	Risk Ratio (M‐H, Random, 95% CI)	1.83 [1.35, 2.50]
5 Graft loss censored for death (CNI comparator)	14	3277	Risk Ratio (M‐H, Random, 95% CI)	1.32 [0.96, 1.81]
5.1 Tacrolimus	5	1238	Risk Ratio (M‐H, Random, 95% CI)	1.95 [1.17, 3.25]
5.2 Cyclosporin	10	2039	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.68, 1.54]
6 Acute rejection (antimetabolite co‐intervention)	6	670	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.81, 1.48]
6.1 Azathioprine	1	83	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.64, 1.85]
6.2 Mycophenolate	5	587	Risk Ratio (M‐H, Random, 95% CI)	1.10 [0.75, 1.59]